Final analysis of KEYNOTE-585: pembrolizumab and chemotherapy in G/GEJ cancer 

Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses the final analysis of the Phase III KEYNOTE-585 trial (NCT03221426), which assessed perioperative pembrolizumab plus chemotherapy versus placebo plus chemotherapy in untreated, locally advanced, resectable gastric and gastroesophageal junction (G/GEJ) cancer. While median event-free survival (EFS) and overall survival (OS) showed trends favoring pembrolizumab plus chemotherapy, the results were not statistically significant. Safety outcomes were consistent across both treatment arms. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.